Repatha Reviewers
Executive Summary
FDA staff involved in review of Amgen's PCSK9 inhibitor evolocumab for reducing LDL-cholesterol.
Repatha FDA Reviewers |
|
Medical |
Eileen Craig |
Chemistry |
Bazzarragchaa Damdinsuren (drug substance); Sang Bong Lee (drug product) |
Clinical Pharmacology |
Suryanarayana Sista; Justin Earp*; Nitin Mehrotra, Jaya Vaidyanathan |
Microbiology |
Michael Shanks (drug substance); Lakshmi Rani Narasimhan (drug product) |
Pharmacology/Toxicology |
C. Lee Elmore* |
Statistics |
Shuxian Sinks; Janelle Charles* |
Cross-Discipline Team Leader |
James Smith* |
Regulatory Project Manager |
Kati Johnson |
*Reviewer worked on both Repatha and Praluent |